Amneal Pharmaceuticals, Inc. AMRX Debt Issuance Cost Amortization
Debt Issuance Cost Amortization at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCostsAndDiscounts.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s debt issuance cost amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s debt issuance cost amortization?
- Amneal Pharmaceuticals, Inc. (AMRX) reported debt issuance cost amortization of $3.89M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s debt issuance cost amortization changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s debt issuance cost amortization decreased by 42.9% year-over-year, from $6.81M to $3.89M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s debt issuance cost amortization?
- Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s debt issuance cost amortization has grown at a 24.9% compound annual growth rate (CAGR), from $9.2M to $22.43M.
- What does debt issuance cost amortization mean?
- Non-cash amortization of capitalized costs incurred to issue debt (underwriting fees, legal costs, SEC filing fees).